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ABSTRACT  
Leptospirosis is a fatal infectious disease caused by different serovars of Leptospira spirochetes affecting humans and animals.  In the present 
study, the trials of the whole-cell killed formalin treated monovalent vaccine using Leptospira icterohaemorrhagiae and trivalent vaccine using 
Leptospira icterohaemorrhagiae, Leptospira louisiana, and Leptospira hebdomadis were studied. The serum electrophoresis studies were done 
after administration of the vaccine into the experimental albino mice along with the booster dose of the vaccinated serum by densitometric 
readings. Similarly, the pathological observations were made by dissecting the virulent mice, vaccinated mice, and comparing them with the 
control mice. The MAT titre was also studied after the booster dose administration of the vaccinated serum. The monovalent and trivalent 
whole-cell killed formalin treated vaccines shows significant raise in the total proteins, albumin, globulin, α 1 globulin, α 2 globulin, β globulin 
and γ globulins of the serum as well as increase in significant levels in the antibody levels after the administration of the  booster dose at an 
interval of 14 days. 
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INTRODUCTION: 
Leptospirosis, a zoonotic disease caused by the spirochetal 
bacteria Leptospira is a common disease of livestock, pet 
animals with its prevalence worldwide 1. The geographical 
distribution of leptospirosis has been overlapping over the 
decades and produce endemic and epidemic acute febrile 
diseases 2. Sporadic outbreaks have been reported from the 
countries like USA, UK, Australia, New Zealand, parts of 
Europe, and among Asian countries. The recent incidence of 
leptospirosis is approximately 1.03 million cases with 58900 
associated deaths that have been reported worldwide 3. In 
India, Ayyar first isolated Leptospira interrogans serovar 
Icterohaemorrhagiae from dogs in Chennai, Tamilnadu, 
India, 4 and from then on the prevalence of leptospirosis 
have been reported in human and animal species 5-8. The 
source of infection occurs through direct or indirect 
exposure to infected reservoir host animals which carry the 
leptospires in their renal tubules and shed it in their urine 9. 
The brown rat (Rattus norvegicus) was considered an 
important source of infection although many wild and 
domestic animals can serve as reservoir hosts. Leptospirosis 
was initially known as Weil's syndrome 10, 11 and is mostly an 
occupational disease affecting humans who come in contact 
with rodents, pets, and polluted water 12-15. The clinical 
features of leptospirosis depend on the host and serovar 
type which may be highly variable and nonspecific. Mostly 
asymptomatic or subclinical infections occur but when 
symptoms appear the onset is typically 2 to 30 days after 
exposure 16. The broad spectrum symptoms of leptospirosis 
include pneumonitis 17, 18, meningitis 19, nephritis 20-23, 
hepatitis 24, pancreatitis 25 and erythema nodosum 26 and 
death 27, 28. The whole-cell killed vaccines were developed 
and available in some countries for prevention during 
endemic and epidemic situations 29. Apart from the whole-
cell killed vaccines other vaccines like recombinant protein 
vaccines, lipopolysaccharide (LPS) vaccines, inactivated and 
attenuated vaccines, and DNA vaccines have been developed 
across worldwide 30. The development of the whole-cell 
killed vaccine and their subsequent trials have been 
reviewed and published in the middle of the last century 31-
34. The targeting and identification of proteins among 
pathogenic leptospires have become one of the major 
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leptospirosis researches as it can provide cross-protection 
on various serovar groups 35-57. In the present study, the 
whole-cell killed formalin treated vaccine preparative trials 
were conducted in albino mice and their immunological 
studies were done using serum electrophoresis by 
densitometric readings and SDS PAGE for determining their 
molecular weight along with the pathological observation of 
the dissected albino mice injected with virulent strains and 
the whole-cell killed formalin treated vaccine prepared 
compared to that of control mice. 
MATERIALS AND METHODS: 
Collection and maintenance of Virulent Leptopspiral 
serovars 
The virulent serovars of Leptospira icterohaemorrhagiae (Fig 
3), Leptospira louisiana (Fig 1), and Leptospira hebdomadis 
(Fig 2) were collected and maintained at Leptospirosis 
Research Cell, Institute of Microbiology, Madras Medical 
College, Chennai, Tamilnadu, India. The Virulent serovars 
were maintained in Ellinghausen McCullough Johnson & 
Harris (EMJH) medium [BD Difco] with a solution of 
albumin, polysorbate 80, and additional growth factors for 
the growth of Leptospira 58-65 and the final pH 7.5 ± 0.2 was 
maintained (Fig 4). The cultures were incubated for 5 to 7 
days at 28-300C and they were checked for the growth and 
purity of leptospires under dark field microscopy 
(Nikon SMZ1500) to see that absence of any contamination 
or clumps or presence of enough quantity of growth. The 
turbidity of the cultures was checked and compared with 1.0 
McFarland‘s standard for the level of growth as to obtain 2-3 
x 108 leptospira /ml of media 66. 
Monovalent and Trivalent vaccine preparation trial for 
Leptospirosis 
The monovalent vaccine was prepared using the serovar 
Leptospira icterohaemorrhagiae and the trivalent vaccine 
was prepared using serovars Leptospira 
icterohaemorrhagiae, Leptospira louisiana, and Leptospira 
hebdomadis at 250 million/ml concentration (Fig 5). The 
cultures were killed with formalin (Merck) (0.5 ml 
formaldehyde) ± 36% in 100 ml culture. They were kept in 
room temperature for 30 minutes and the killed leptospires 
were then heated in a boiling water bath (950C) for 30 
minutes. They were rotated every 15 minutes and then 
cooled at room temperature 67-70.  
Experimental inoculation in albino mice 
The albino mice were procured from Tamilnadu Veterinary 
and Animal Sciences University (TANUVAS), Madavaram, 
Chennai, Tamilnadu, India. The mice weighed in the range of 
18-20 g in weight. The procured albino mice were brought 
and maintained at Animal House at Jaya College of Arts & 
Science, Chennai, Tamilnadu, India. The mice were 
maintained separately with proper housing and ventilation. 
Box type cages were maintained as mice required shaded 
light with proper bedding materials like sawdust, paddy 
husk, sugarcane pith, and wood shavings and thoroughly 
changed at regular intervals. The sanitary condition of the 
cage is thoroughly checked and cleaned at regular intervals. 
The feeders and waterers are thoroughly disinfected using 
moist heat sterilization. 
The prepared monovalent and trivalent vaccine was injected 
into the albino mice at 0.05 ml concentration 
intramuscularly along with Freund’s complete adjuvant 
(Sigma-Aldrich) 71. Before inoculation, the albino mice were 
tested for germ-free status without any infections. 
Determination of Serum Globulin profile of inoculated 
albino mice 
Cardiac puncture of albino mice was made by piercing the 
needle through skin and musculature of the left intercostal 
space between sixth and seventh ribs 72. The heart was 
palpated before the introduction of the needle and the blood 
was drawn carefully with 1 ml tuberculin needle and the 
serum was separated by centrifugation (REMI – R8C). The 
separated serum from the monovalent and trivalent injected 
albino mice was compared with the serum of control mice by 
serum electrophoresis and densitometric readings. 
Serum Electrophoresis 
The procured serum from monovalent injected mice, 
trivalent injected mice, and control mice were subjected to 
serum electrophoresis. 1% Agarose was prepared in the tris-
glycine buffer and 3.5 ml of agarose solution was carefully 
poured onto a clean glass slide using a pipette that was 
allowed to form a gel for 15-20 minutes. A few drops of 
undiluted serum were pipetted on to a clean glass slide and a 
pinch of bromophenol blue powder was added over it. Then 
the serum was mixed using a coverslip and stamped on to 
the gel at one end of the slide. The slide was then placed over 
the bridges of the apparatus and 75 -100 ml of Tris-glycine 
buffer was poured to each reservoir. The Whatmann -1 filter 
paper (3.0 x 2.5 cm) was wetted in the buffer and place on 
each side of the gel side and the other end of the paper wick 
was allowed to touch the buffer. The apparatus was 
connected to the power supply which was turned on for the 
electron mobility to run over the gel and the voltage was 
slowly increased to 100 volts. The gel was allowed to run for 
1 to 2 hours till the blue color marker dye reaches the anodic 
end of the gel. Finally, the power supply was disconnected 
and the slides were removed and placed in a tray for staining 
purpose 73. After staining the slides were removed and dried 
which were examined for bands on white light trans-
illuminator (BIO-HELIX - BP001CU). The slides were finally 
subjected to densitometric readings. 
Microscopic Agglutination Test (MAT)  
The MAT is a qualitative and quantitative test having high 
diagnostic specificity and relatively low sensitivity. The 
microscopic agglutination test (MAT) is the reference test 
method for the sero-diagnosis of leptospirosis both in 
humans and in animals (World Health Organization (WHO), 
2003; World Organization for Animal Health (OIE), 2008). 
This test detects antibodies to specific serovars using live 
leptospiral antigens and can be performed on serum from 
any species. The serum obtained from the vaccinated 
experimental mice was given subsequent booster doses at 
the time interval of 14 days in the range of 1st, 2nd & 3rd and 
the antibody level was determined by Microscopic 
Agglutination Test (MAT) 74. 
Pathological Studies: 
The pathological studies were performed by dissecting the 
mice [virulent mice, vaccinated mice, and control mice] and 
their physical internal body parts were observed and 
reported 75.  
RESULTS: 
The whole-cell heat-killed formalin treated monovalent 
vaccine was prepared using single serovar Leptospira 
icterohaemorrhagiae and a trivalent whole-cell heat-killed 
formalin treated vaccine was prepared using serovars 
Leptospira icterohaemorrhagiae, Leptospira louisiana, and 
Leptospira hebdomadis. The vaccines monovalent and 
trivalent were then injected into albino mice (Include 
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conditions) intramuscularly and their serum profile was 
observed by densitometric readings compared with the 
virulent injected albino mice serum and the control mice 
serum. The densitometric readings of the serum 
electrophoresis revealed the presence of total proteins, 
albumin, globulin, α 1 globulin, α 2 globulin, β globulin, and γ 
globulins in the monovalent, trivalent and virulent injected 
mice serum as well as in the control mice serum. The total 
proteins, albumin, globulin, α 1 globulin, α 2 globulin, β 
globulin and γ globulins showed a significant increase in 
monovalent vaccine injected serum (Fig 7; Graph 2) when 
compared to control mice serum (Fig 6; Graph 1) and a 2 
fold increase of total proteins, albumin, globulin, α 1 
globulin, α 2 globulin, β globulin, and γ globulins were 
observed in trivalent vaccine injected serum (Fig 8; Graph 
3). The booster dose of the monovalent and trivalent 
vaccines along with Freund’s adjuvant was given at an 
interval of every 14 days interval and the antibody level was 
determined. The microscopic agglutination titre (MAT) (Fig 
9 & 10) revealed the significant increase in the antibody 
levels after the administration of the booster dose in the 
ratio 1:05 (1st booster dose), 1:20 (2nd booster dose) and 
1:40 (3rd booster dose). The pathological studies revealed 
the enlargement of internal organs of the virulent strains 
injected albino mice such as spleen, liver, heart intestine, etc. 
which were absent when compared with the control and 
vaccinated albino mice.  
DISCUSSION: 
The whole-cell killed formalin treated vaccines from the 
present study showed a significant increase in the serum 
profile when compared to control mice serum especially 2 
fold increase was observed with trivalent injected vaccine 
serum. Similarly, the antibody levels by microscopic 
agglutination test showed an increase in the antibody levels 
on every booster dose at an interval of 14 days. It is known 
that heat or chemical treatment of leptospires changes their 
effectiveness as vaccines. The phenol, Formalin, and 
thimerosal remove the outer envelope and damage the 
protoplasmic cylinder was reported during 1965 in an 
ultrastructure study 76. It is known that Formalin treated 
antigens have lower sensitivity and greater cross-reactivity 
in the MAT 77. The effectiveness of the killed vaccine is 
serovar specific which was documented in various studies 78, 
79. The variability of serovars in the locality of endemic 
leptospiral strains makes it difficult to construct a vaccine 
that can be used worldwide 80. Studies revealed that heat-
killed inactivated vaccine induces a strong antigen-specific 
proliferative response by peripheral blood mononuclear 
cells (PBMC) which was reported in vaccinated cattle after 2 
months of the initial booster dose 81. The whole-cell killed 
vaccine in the study illustrated that the antibody levels were 
low [1:05] during first booster dose and the significant 
increase in the antibody levels were observed in the 2nd 
booster dose (1:20) and 3rd booster dose (1:40) so this 
confirms an elevated immune response after successive 
booster doses (Graph 4) 82. The pathological studies 
confirmed that the vaccinated mice (Fig 13) showed no 
significant change when compared to that of control mice 
(Fig 11) in the internal body organs whereas the 
combination of virulent serovars injected into the albino 
mice (Fig 12) showed severe enlargement of the organs such 
as spleen, liver, pancreas, etc. The results from the serum 
electrophoresis and densitometric readings, antibody 
elevation levels of the vaccinated animals confirmed from 
MAT titers as well as the pathological studies confirm and 
form the basis for the development of potent leptospiral 
vaccines for both epidemic and endemic cases of 
leptospirosis with new molecular biological tools and 
advance research systems. 
 
 
 
Figure 1: Leptospira louisiana under Fluorescence Microscopy 
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Figure 2: Leptospira hebdomadis under High Power Microscopy 
 
Figure 3: Leptospira icterohaemorrhagiae under Scanning Electron Microscopy 
 
Figure 4: Virulent serovars of Leptospira icterohaemorrhagiae, Leptospira louisiana, and Leptospira hebdomadis in 
EMJH enriched media. 
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Figure 5: Whole-cell killed formaldehyde-treated monovalent and trivalent vaccine 
 
Figure 6: Electropherogram of control albino mice serum 
 
Figure 7: Electropherogram of monovalent albino mice serum 
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Figure 8: Electropherogram of trivalent albino mice serum 
 
Graph 1: Serum profile of the control albino mice 
 
Graph 2: Serum profile of the monovalent vaccinated albino mice 
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Graph 3: Serum profile of the trivalent vaccinated albino mice 
 
Graph 4: Antibody levels of 3 booster doses with Freund’s adjuvant [14 days interval] 
 
Figure 9: Positive reaction of microscopic agglutination test [MAT] 
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Figure 10: Negative reaction of microscopic agglutination test [MAT] 
 
 
Figure 11: Pathological observation of the dissected control mice 
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Figure 12: Pathological observation of the dissected virulent mice 
 
Figure 13: Pathological observation of the dissected Vaccinated mice 
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